Roivant Doses First Patient in Pivotal BREATHE Clinical Trial Evaluating Gimsilumab in COVID-19 Patients for the Prevention and Treatment of Acute Respiratory Distress Syndrome

NEW YORK and BASEL, Switzerland, April 15, 2020 / PRNewswire -- Roivant Sciences announced today that the first patient was dosed at Temple University Hospital in Philadelphia in an adaptive, randomiz

Latest News Clinical News 721
Read All

Oragenics, Inc. Announces Early Top-Line Results of Phase 2 Clinical Trial of AG013 for Oral Mucositis in Chemoradiation Treatment of Head and Neck Cancer

TAMPA, Fla.--(BUSINESS WIRE) April 15, 2020 -- Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucos

Latest News Clinical News 938
Read All

FDA Approves Initiation of Humanigen’s Phase III Study of Lenzilumab in COVID-19 Patients

Burlingame, CA, April 15, 2020 -- Humanigen, Inc., (HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating cytokine storm with lenzilumab, the company’s pro

Latest News Clinical News 949
Read All

Alnylam Receives Fast Track Designation for Vutrisiran for the Treatment of the Polyneuropathy of hATTR Amyloidosis

CAMBRIDGE, Mass.-(BUSINESS WIRE)--Apr. 14, 2020 -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the U.S. Food and Drug Administration (FDA)

Latest News Clinical News 1240
Read All

Sinovac Announces Approval of Human Clinical Trial for a Vaccine Candidate Against COVID-19

BEIJING - April 14, 2020 -- Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the Company has obtained app

Latest News Clinical News 743
Read All

Aldeyra Announces Positive Top-Line Phase 1 Clinical Trial Results and Clinical Development Plans for ADX-629

LEXINGTON, Mass.--(BUSINESS WIRE)-Apr. 14, 2020 -- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the po

Latest News Clinical News 834
Read All

AstraZeneca Initiates CALAVI Clinical Trial with Calquence Against COVID-19

April 14, 2020 -- AstraZeneca will initiate a randomised, global clinical trial to assess the potential of Calquence (acalabrutinib) in the treatment of the exaggerated immune response (cytokine storm

Latest News Clinical News 1343
Read All

Sanofi and GSK to Join Forces in Unprecedented Vaccine Collaboration to Fight COVID-19

PARIS and LONDON – April 14, 2020 -- Sanofi and GSK today announce that they have signed a letter of intent to develop an adjuvanted vaccine for COVID-19, using innovative technology from both compani

Latest News Clinical News 805
Read All

Lilly Begins Clinical Testing of Therapies for COVID-19

INDIANAPOLIS, April 10, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today it has entered into an agreement with the National Institute of Allergy and Infectious Diseases (NIAID),

Latest News Clinical News 1009
Read All

Data on 53 Patients Treated With Investigational Antiviral Remdesivir Through the Compassionate Use Program Published in New England Journal of Medicine

FOSTER CITY, Calif.--(BUSINESS WIRE)--Apr. 10, 2020 -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from a cohort analysis of 53 patients hospitalized with severe complications of COVI

Latest News Clinical News 709
Read All

Relief Therapeutics Drug Aviptadil Enters FDA Trial at Thomas Jefferson University Hospital in Philadelphia, to treat COVID-19-Induced Acute Respiratory Distress

Geneva, Switzerland: April 9, 2020 -- RELIEF THERAPEUTICS Holding AG (SIX:RLF) “Relief” announces that its drug Aviptadil has now entered FDA clinical trials at Thomas Jefferson University Hospital in

Latest News Clinical News 754
Read All

Fujifilm Announces the Start of a Phase II Clinical Trial of its Influenza Antiviral Drug “Avigan® Tablet” for COVID-19 Patients in the U.S.

TOKYO, April 9, 2020 -- FUJIFILM Corporation (President: Kenji Sukeno) announces the initiation of a U.S. phase II clinical trial to evaluate the safety and efficacy of its influenza antiviral drug “A

Latest News Clinical News 805
Read All
News
- CLINIEXPERT -
Int'l Clinical Service Expert

We are the leader
Because of our professionism